All In MedTech

FDA Clearance Tracker · P930038-S052

ANGIO-SEAL VASCULAR CLOSURE DEVICE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 26, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 26, 2008

Approved

Time to decision

273 days

Received Dec 28, 2007. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P930038-S052
Device name
ANGIO-SEAL VASCULAR CLOSURE DEVICE
Applicant location
Elkton, MD
Received
Dec 28, 2007
Decided
Sep 26, 2008
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P930038

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MGB

FDA's approval statement

As written in FDA's record.

APPROVAL FOR USE OF THE ANGIO-SEAL VASCULAR CLOSURE DEVICE IN CLOSURE OF FEMORAL VENOUS PUNCTURE SITES AND FOR THE REMOVAL OF THE PRECAUTION STATEMENT RELATING TO THE USE OF THE ANTICOAGULANT WARFARIN. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ANGIO-SEAL VASCULAR CLOSURE DEVICE AND IS INDICATED FOR USE IN CLOSING AND IN REDUCING TIME TO HEMOSTASIS AT THE FEMORAL ARTERIAL AND FEMORAL VENOUS PUNCTURE SITE IN PATIENTS WHO HAVE UNDERGONE DIAGNOSTIC ANGIOGRAPHY OR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) PROCEDURES USING AN 8 FRENCH OR SMALLER PROCEDURAL SHEATH.

Source documents

Other decisions for Terumo Medical Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.